Abstract PO-076: Murine adapted FOLFIRINOX for standard-of-care in KPC mice

Abstract Until relatively recently, the standard-of-care (SOC) treatment for pancreas cancer was not appreciably superior to best supportive care in prolonging life, and potentially new treatment strategies had a relatively modest bar to surmount. New combination regimens have emerged and novel therapies should therefore be compared against the current SOC. However, in preclinical development of novel agents, efficacy is frequently compared against vehicle control and less commonly against cytotoxic chemotherapy. Furthermore, virtually all studies of cytotoxic chemotherapy for PDA in mice have used gemcitabine (gem) monotherapy as standard-of-care, although this is no longer the standard for this disease. One of the current standard regimens, gem+nab-paclitaxel, cannot be given in mice without inducing immune responses because of the incorporation of human albumin in developing the taxol nanoparticles. The other new standard, FOLFIRINOX, is a complex 4-agent regimen that includes a 46-hour continuous infusion component that has been prohibitively challenging to deliver to animals. We have now built an appropriate dosing regimen incorporating these 4 agents that required a deliberate, step-by-step, program of empiric testing of the drugs, first, one at a time, then in various doublets and triplets, and, finally, as a whole regimen. The studies included close clinical evaluations and serial blood tests to follow complete blood counts (CBC). We have incorporated this regimen as the new SOC in our Murine Clinical Trials Program (MCTP). We propose that this mur-FOLIFIRINOX regimen should represent the new standard for murine studies. Citation Format: Martin C. Whittle, Aditi Palkar, Rachael Fasnacht, James Yan, Borith Kheng, Kianna Sinfuego, Shelley Thorsen, Sunil R. Hingorani. Murine adapted FOLFIRINOX for standard-of-care in KPC mice [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-076.